• / Free eNewsletters & Magazine
  • / My Account
Home>Companies>Bayer AG

Bayer AG

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Research and Markets: Regeneron and Bayer AG's Eylea (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

    Research and Markets: Regeneron and Bayer AG's Eylea (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023

  2. Regeneron Wins Expanded Approval for Eye Drug Elyea

    Regeneron Wins Expanded Approval for Eye Drug Elyea

  3. Asahi Kasei Pharma Selects Evotec as Its Partner for Ion Channel Drug Discovery

    Asahi Kasei Pharma Selects Evotec as Its Partner for Ion Channel Drug Discovery

  4. Takeda Licenses Rights to Use ImmunoGen, Inc.’s Novel Antibody-Drug Conjugate Technology

    Takeda Licenses Rights to Use ImmunoGen, Inc.’s Novel Antibody-Drug Conjugate Technology

  5. Natrel Repositions to Offer Healthcare Marketers an Unobstructed Path to Brand Differentiation

    Natrel Repositions to Offer Healthcare Marketers an Unobstructed Path to Brand Differentiation

  6. Research and Markets: Australia Sleep Apnea Diagnostic Systems Market Growth Trends Report 2015

    Research and Markets: Australia Sleep Apnea Diagnostic Systems Market Growth Trends Report 2015

  7. Research and Markets: Type 2 Diabetes Therapeutics Pipeline Review 2015 - Featuring Over 200 Companies

    Research and Markets: Type 2 Diabetes Therapeutics Pipeline Review 2015 - Featuring Over 200 Companies

  8. Research and Markets: Liver Cancer Partnering Deals and Agreements 2010-2015 - Analysis from the World's Leading Healthcare Companies

    Research and Markets: Liver Cancer Partnering Deals and Agreements 2010-2015 - Analysis from the World's Leading Healthcare Companies

  9. Bayer Suspends Enrollment for Phase III Trial of Regorafenib for Colorectal Cancer

    Bayer Suspends Enrollment for Phase III Trial of Regorafenib for Colorectal Cancer

  10. Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent™ (alirocumab) Published in The New England Journal of Medicine

    Regeneron and Sanofi Announce 18-Month Results of ODYSSEY LONG TERM Trial with Praluent™ (alirocumab) Published in The New England Journal of Medicine

1234
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.